Home › Compare › MTPOY vs ABBV
MTPOY yields 4.71% · ABBV yields 3.06%● Live data
📍 MTPOY pulled ahead of the other in Year 1
Combined, MTPOY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MTPOY + ABBV for your $10,000?
Metropolitan Bank & Trust Company, together with its subsidiaries, provides various commercial and investment banking products and services in the Philippines, rest of Asia, the United States, and Europe. The company's Consumer Banking segment offers consumer type loans and support for the sourcing and generation of consumer business. Its Corporate Banking segment engages in handling loans and other credit facilities; and provides deposit and current accounts for corporate and institutional customers. The company's Investment Banking segment offers structured financing; services relating to privatizations, initial public offerings, and mergers and acquisitions; and advisory services to individuals and institutions. Its Treasury segment provides money market, trading, and treasury services. The company's Branch Banking segment handles branch deposits, as well as offers loans and other loan related products for middle market clients. Its Others segment provides remittances, leasing, account financing, and other support services. The company also provides trade finance, thrift banking, foreign fund transfer, foreign exchange, online and mobile banking, collateral, and trust services. It operates through a network of 701 branches and 1,770 automated teller machines. The company was incorporated in 1962 and is headquartered in Makati City, the Philippines.
Full MTPOY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.